drugset
drugset / Trial / NCT01218100

Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension

NCT01218100 ↗

Phase 4 Completed 664 enrolled Forest Laboratories
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will evaluate the safety and efficacy of first-line treatment with a free combination (as two separate pills) of nebivolol and lisinopril in patients with stage 2 diastolic hypertension (DBP\>= 100 mmHg).

Timeline

Start
2010-10
Primary completion
2011-05
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject LISINOPRIL ANHYDROUS Small molecule 10 mg Oral
Subject LISINOPRIL ANHYDROUS Small molecule 40 mg Oral
Subject Nebivolol Other / unclassified 5 mg Oral
Subject Nebivolol Other / unclassified 20 mg Oral

Indications

hypertensive disorder